Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dopamine and Somatostatin Analogues Resistance of Pituitary Tumors: Focus on Cytoskeleton Involvement

22 Dec 2015

Abstract excerpt

Pituitary tumors, that origin from excessive proliferation of a specific subtype of pituitary cell, are mostly benign tumors, but may cause significant morbidity in affected patients, including visual and neurologic manifestations from mass-effect, or endocrine syndromes caused by hormone hypersecretion. Dopamine (DA) receptor DRD2 and somatostatin (SS) receptors (SSTRs) represent the main targets of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Growth Hormone and Insulin-like Growth Factors
Share to Neuroendocrine Tumor Research Advances
Share to Pituitary Gland Disorders and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26733942
DOI: 10.3389/fendo.2015.00187

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dopamine and Somatostatin Analogues Resistance of Pituitary Tumors: Focus on Cytoskeleton InvolvementPMID 26733942Read ↗

Filamin-A Is Essential for Dopamine D2 Receptor Expression and Signaling in Tumorous LactotrophsSemantic proximity Read ↗

Filamin A (FLNA) Plays an Essential Role in Somatostatin Receptor 2 (SST2) Signaling and Stabilization After Agonist Stimulation in Human and Rat Somatotroph Tumor CellsSemantic proximity Read ↗

Pituitary Tumors: Genetic and Molecular Factors Underlying Pathogenesis and Clinical BehaviorSemantic proximity Read ↗

Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profilesSemantic proximity Read ↗

The 2017 WHO classification of pituitary adenoma: overview and comments.Semantic proximity Read ↗

Epithelial-Mesenchymal Transition in the Resistance to Somatostatin Receptor Ligands in Acromegaly.Semantic proximity Read ↗

A growth hormone receptor mutation impairs growth hormone autofeedback signaling in pituitary tumors.Semantic proximity Read ↗

Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomasSemantic proximity Read ↗

Dopamine Agonists for the Treatment of Pituitary Tumors: From Ergot Extracts to Next Generation TherapiesSemantic proximity Read ↗

A Role for Mitogen- and Stress-Activated Kinase 1 in L-DOPA –Induced Dyskinesia and ∆FosB ExpressionSemantic proximity Read ↗

Differential actions of the dopamine agonist bromocriptine on growth of SMtTW tumors exhibiting a prolactin and/or a somatotroph cell phenotype: relation to dopamine D2 receptor expression.Semantic proximity Read ↗

A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.